MacroGenics Sells Manufacturing Arm for $122.5M, Sharpens Focus on Pipeline
Event summary
- MacroGenics sold its GMP manufacturing operations to Bora for $122.5M in July 2026, reducing workforce to ~140 employees
- Pro forma cash position stands at $327M with runway guidance through 2028
- Key pipeline updates include ESMO presentations for MGC026 and lorigerlimab, plus IND clearance for MGC030
- Gilead exercised option on preclinical bispecific program, triggering $10M payment
The big picture
MacroGenics' manufacturing divestiture reflects a broader biotech trend of outsourcing non-core functions to focus on R&D. The $327M pro forma cash position provides significant operational flexibility, but the company's ability to deliver meaningful clinical data will determine its valuation multiple in this competitive oncology space.
What we're watching
- Pipeline Momentum
- Whether MGC026's SCCHN cohort success translates to other tumor types and whether late-2026 MGC028 results meet expectations.
- Financial Discipline
- The pace at which MacroGenics can maintain cost efficiency while advancing multiple clinical programs simultaneously.
- Partnership Leverage
- How effectively MacroGenics can monetize its existing collaborations, particularly with Gilead and Sanofi, to extend cash runway beyond 2028.
Related topics